Merck & Co.

Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Rising Incidences Of Idiopathic Intracranial Hypertension to Boost Growth | Technavio

Monday, June 1, 2020 - 9:00pm

Our idiopathic intracranial hypertension therapeutics market report covers the following areas:

Key Points: 
  • Our idiopathic intracranial hypertension therapeutics market report covers the following areas:
    This study identifies an increasing number of awareness campaigns as one of the prime reasons driving the idiopathic intracranial hypertension therapeutics market growth during the next few years.
  • Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Vendor Analysis
    We provide a detailed analysis of around 25 vendors operating in the Idiopathic Intracranial Hypertension Therapeutics Market, including some of the vendors such as AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
  • Backed with competitive intelligence and benchmarking, our research reports on the Idiopathic Intracranial Hypertension Therapeutics Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Key Highlights

Immunotherapy Drugs Market Worth $274.6 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Friday, May 29, 2020 - 3:30pm

On the basis of type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapy drugs.

Key Points: 
  • On the basis of type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapy drugs.
  • The mAbs segment accounted for the largest share of the immunotherapy drugs market in 2019.
  • Cancer commanded the largest share of the immunotherapy drugs market, by therapeutic area, in 2019.
  • F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), and Merck & Co (US) are the key players operating in the immunotherapy drugs market.

Immunotherapy Drugs Market Worth $274.6 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Friday, May 29, 2020 - 3:30pm

On the basis of type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapy drugs.

Key Points: 
  • On the basis of type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapy drugs.
  • The mAbs segment accounted for the largest share of the immunotherapy drugs market in 2019.
  • Cancer commanded the largest share of the immunotherapy drugs market, by therapeutic area, in 2019.
  • F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), and Merck & Co (US) are the key players operating in the immunotherapy drugs market.

Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate

Thursday, May 28, 2020 - 8:01pm

Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ USA, has exercised its option to utilize Vaxxas proprietary High Density Microarray Patch (HD-MAP) platform for a vaccine candidate.

Key Points: 
  • Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ USA, has exercised its option to utilize Vaxxas proprietary High Density Microarray Patch (HD-MAP) platform for a vaccine candidate.
  • "We are excited by this latest milestone in our collaboration with MSD, an early adopter of our novel HD-MAP platform, stated Vaxxas Chief Executive Officer, David L. Hoey.
  • With their strong legacy of vaccine development MSD is a tremendous partner in our efforts to enhance the efficiency, effectiveness, and reach of vaccination.
  • Vaxxas will receive US$12 million (A$18 million) in a combination of equity funding and option fees associated with the agreement.

RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s KEYTRUDA® for Certain Late-Stage Cancers

Thursday, May 28, 2020 - 2:00pm

This image depicts two 90-degree PET arcs that sense tumor emissions to guide radiotherapy delivery.

Key Points: 
  • This image depicts two 90-degree PET arcs that sense tumor emissions to guide radiotherapy delivery.
  • Worldwide, over 1,000 clinical trials registered with the National Institutes of Health seek to determine the effect of combining immunotherapy and radiotherapy.
  • Currently, the RefleXion machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT), all different techniques of EBRT.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Themis to be Acquired by MSD

Tuesday, May 26, 2020 - 11:51am

Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer and MSD (trademark of Merck & Co., Inc., Kenilworth, N.J., USA, NYSE: MRK) today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis.

Key Points: 
  • Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer and MSD (trademark of Merck & Co., Inc., Kenilworth, N.J., USA, NYSE: MRK) today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis.
  • Under terms of the agreement, MSD, through a subsidiary, will acquire all outstanding shares of Themis in exchange for an undisclosed cash payment.
  • Upon completion of the deal Themis will become a wholly-owned subsidiary of MSD.
  • This acquisition by MSD, a global leader in vaccine development, reflects Themis success in applying our versatile immune-modulation platform that builds on the original discoveries from the Institut Pasteur, said Dr. Erich Tauber, chief executive officer, Themis.

Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients

Wednesday, May 20, 2020 - 12:05pm

SRF617 inhibits CD39, an enzyme critical both to the breakdown of adenosine triphosphate (ATP) and the production of adenosine.

Key Points: 
  • SRF617 inhibits CD39, an enzyme critical both to the breakdown of adenosine triphosphate (ATP) and the production of adenosine.
  • A substantial body of research supports a role for CD39 in allowing cancer to evade immune responses.
  • The combination of SRF617 and KEYTRUDA has the potential to overcome this barrier to immune system activation and promote anti-tumor immunity.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting

Thursday, May 14, 2020 - 1:22am

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Key Points: 
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer.
  • There is no guarantee that any investigational compounds and investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma

Wednesday, May 13, 2020 - 10:00pm

Von Hippel-Lindau disease is a rare hereditary condition affecting multiple organs, which puts patients at risk for several cancers, including renal cell carcinoma.

Key Points: 
  • Von Hippel-Lindau disease is a rare hereditary condition affecting multiple organs, which puts patients at risk for several cancers, including renal cell carcinoma.
  • Follow Merck on Twitter via @Merck and keep up to date with ASCO news and updates by using the hashtag #ASCO20.
  • This study is a Phase 2, open-label, single-arm trial evaluating MK-6482 for the treatment of VHL-associated ccRCC (ClinicalTrials.gov, NCT03401788 ).
  • Patients received MK-6482 120 mg orally once daily until disease progression, unacceptable toxicity, or investigators or patients decision to withdraw.

Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals

Wednesday, May 13, 2020 - 7:00am

Merck Animal Health will make a cash payment of approximately $400 million to acquire the SENTINEL branded products in the United States at closing of the acquisition.

Key Points: 
  • Merck Animal Health will make a cash payment of approximately $400 million to acquire the SENTINEL branded products in the United States at closing of the acquisition.
  • Veterinary medicines, including parasiticides, and vaccines have transformed the health of animals over the past decade, said Rick DeLuca, president, Merck Animal Health.
  • This product acquisition reinforces Merck Animal Healths commitment to our customers and our position in the United States Companion Animal category.
  • Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck.